K
Kyung Nam Pharm Co Ltd
KOSDAQ:053950
Kyung Nam Pharm Co Ltd
KOSDAQ:053950
Price:
642
KRW
-2.58%
Market Closed
Market Cap:
₩50.2B
Kyung Nam Pharm Co Ltd
Research & Development
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Kyung Nam Pharm Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kyung Nam Pharm Co Ltd
KOSDAQ:053950
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Research & Development
-₩197B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-19%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Research & Development
-₩162.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Research & Development
-₩195.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Research & Development
-₩8.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Research & Development
-₩5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Kyung Nam Pharm Co Ltd
Glance View
Kyungnam Pharm Co., Ltd. manufactures pharmaceutical products. The company is headquartered in Uiryeong-Gun, Gyeongsangnam-Do. The company went IPO on 2001-11-06. The firm's product portfolio consists of vitamin products, placenta products, health food products and general pharmaceuticals. The firm provides vitamin products under the brand name LEMONA. The company supplies health food products such as lactobacillus products through convenient stores and marts. The placenta products include human placenta related injections and drinks. The general pharmaceuticals include athlete foot therapeutic agents, inflammatory drugs, cold remedies, multi-nutrients and others.
Intrinsic Value
816.32
KRW
Undervaluation 21%
K
